stoxline Quote Chart Rank Option Currency Glossary
SQZ Biotechnologies Company (SQZ)
0.435  0.165 (61.11%)    07-03 13:00
Open: 0.40995
High: 0.5678
Volume: 30,141,624
Pre. Close: 0.27
Low: 0.38
Market Cap: 13(M)
Technical analysis
2023-10-20 4:26:35 PM
Short term     
Mid term     
Targets 6-month :  0.12 1-year :  0.17
Resists First :  0.1 Second :  0.14
Pivot price 0.08
Supports First :  0.04 Second :  0.03
MAs MA(5) :  0.05 MA(20) :  0.09
MA(100) :  0.37 MA(250) :  1.09
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  3.9 D(3) :  3.8
RSI RSI(14): 30.6
52-week High :  3.38 Low :  0.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SQZ ] has closed above bottom band by 12.4%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.06 - 0.06 0.06 - 0.06
Low: 0.05 - 0.05 0.05 - 0.05
Close: 0.05 - 0.05 0.05 - 0.05
Company Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Headline News

Thu, 09 Nov 2023
SQZ lays off off 80% of staff, Regenxbio also reduces head count - FierceBiotech

Wed, 08 Nov 2023
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates -

Thu, 10 Aug 2023
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates - Yahoo Finance

Wed, 26 Jul 2023
Roche declines to take up option on SQZ Bio's SQZ-APC-HPV program - The Pharma Letter

Tue, 25 Jul 2023
Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch - Pharmaceutical Technology

Tue, 25 Jul 2023
SQZ Biotechnologies Provides Update on Collaboration with Roche - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.63
EBITDA (p.s.) -2.43
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0.08
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android